Cipher Pharmaceuticals, Inc. (CPHR) - NASDAQ
  • Apr. 13, 2015, 9:55 AM
    • Cipher Pharmaceuticals (CPHR +15.1%) acquires privately-held Innocutis Holdings LLC for $45.5M in cash. The dermatology firm posted more than $10M in sales in 2014. Cipher expects the deal to be accretive to earnings within two years.
    • Cipher President & CEO Joe Pecora says, "Today's transaction marks or commercial entry to the U.S. market and represents an important step toward our goal of creating a leading North American dermatology business. Innocutis provides us with commercial infrastructure, revenue-generating branded prescription products and a talented team, including a 31-person sales force, that shares our customer-focused philosophy."
    | Apr. 13, 2015, 9:55 AM | 1 Comment
  • Jan. 9, 2015, 9:42 AM
    • Cipher Pharmaceuticals (CPHR) acquires Hershey, PA-based Melanovus Oncology for an upfront payment of $500K as well as the payment of certain IP expenses related to patent prosecution and maintenance.
    • Melanovus' lead product candidate is Nanolipolee-007, a liposomal formulation of a plant-derived cholesterol-transport inhibitor that has demonstrated anti-proliferative activity against certain melanomas.
    | Jan. 9, 2015, 9:42 AM | 1 Comment
Company Description
Cipher Pharmaceuticals Ltd. is a pharmaceutical company, which is focused on commercializing novel formulations of marketed molecules by using advanced drug delivery technologies. The company has three in-licensed products, which includes Lipofen, Conzip/Durela and CIP-ISOTRETINOIN. The Lipofen... More
Sector: Healthcare
Industry: Drug Related Products
Country: Canada